Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 17:22 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 20
March 31, 2026 17:14 ET | Source: Canadian Council for Indigenous Business

Statement: CCIB Response to the Office of the Procurement Ombud’s Procurement Practice Review of Contracts Awarded to Indigenous Businesses Report

TORONTO, ON, March 31, 2026 (GLOBE NEWSWIRE) -- Canadian Council for Indigenous Business (CCIB) welcomes last week’s findings from the Procurement Ombudsman. This report serves as a vital course...
March 31, 2026 16:40 ET | Source: POET Technologies Inc.

POET Technologies Reports Fourth Quarter 2025 Financial Results

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of Photonic Integrated Circuits (PICs),...
March 31, 2026 16:40 ET | Source: Micron Technology, Inc.

Micron Announces the Pricing of the Cash Tender Offers for Any and All of Certain Outstanding Senior Notes

BOISE, Idaho, March 31, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq:MU), (the "Company" or "Micron") announced today the Reference Yield and Notes Consideration (as summarized in the...
March 31, 2026 16:34 ET | Source: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:...
March 31, 2026 16:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 ...
March 31, 2026 16:20 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
March 31, 2026 16:15 ET | Source: Nanobiotix S.A.

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2025

Le programme de développement global de JNJ-1900 (NBTXR3) a progressé comme prévu, ouvrant la voie à une opportunité d’adresser l’un des plus grands marchés encore inexploités en oncologie grâce aux...
March 31, 2026 16:15 ET | Source: Nanobiotix S.A.

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck...
March 31, 2026 16:05 ET | Source: Workhorse Group, Inc.

Workhorse Group Reports Fourth Quarter and Full Year 2025 Results

Revenue of $9.7 million in Q4 2025, up 64% year-over-year; full year revenue of $21.2 million, up 201% year-over-yearOn a pro forma basis, combined company revenue of $34.0 million for full year 2025,...